MRZM hitting radars http://wallstreetnewscast.com/mrzm-0317/
Here is a breakdown of Marizyme current pipeline products:
MB101 – Therapy for Complex Infected Wounds & Burns: Completed Phase 1 trials
MB102 – Therapy for Acute Ischemic Stroke: Nearing end of pre-clinical stage
MB103 – Therapy for Ischemic Myocardial Infarcs: Halfway through pre-clinical stage
MB104 – Therapy for Deep Vein Thrombosis: Early pre-clinical stage
Research Coverage Initiated
Ludlow Research, a small cap equity research firm based in New York City, announced it had initiated research coverage on Marizyme (MRZM) based on their unique treatment for ischemic stroke, and high retail demand for biotechnology investments.
To get a feel of the potential MRZM holds one can look at Hancock Jaffe Laboratories (NASDAQ: HJLI), which develops bioprosthetic (tissue based) medical devices to establish improved standards of care for treating cardiac and vascular diseases. HJLI stock recently caught investors interest spiking from $1.40 to nearly $3.50 on positive earnings, and closure of funding for the company.
Portola Pharmaceuticals (NASDAQ: PTLA) is another player in this field that’s focused on the discovery, development and commercialization of novel therapeutics that could significantly advance the fields of thrombosis and other hematologic diseases.
Register for Research Report Update
To receive an updated copy of Ludlow Research’s report on MRZM register online at https://ludlowresearch.com/investors